DIASORIN SPA EUR1 (NASDAQ:DSRLF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, October 6th. The brokerage presently has a $99.00 price objective on the stock.
According to Zacks, “DiaSorin S.p.A. engages in the development, production and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which serves infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology clinical areas. DiaSorin S.p.A. is headquartered in Vercelli, Italy. “
Shares of DIASORIN SPA EUR1 (NASDAQ:DSRLF) opened at 93.25 on Friday. The stock has a 50 day moving average price of $86.69 and a 200 day moving average price of $85.58. DIASORIN SPA EUR1 has a one year low of $54.50 and a one year high of $93.25. The stock has a market capitalization of $5.11 billion and a P/E ratio of 34.20.
COPYRIGHT VIOLATION WARNING: This piece was published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/diasorin-spa-eur1-dsrlf-rating-increased-to-buy-at-zacks-investment-research/1703302.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DIASORIN SPA EUR1 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIASORIN SPA EUR1 and related companies with our FREE daily email newsletter.